ASPYRE-Lung enables the detection of key genetic mutations from tissue or liquid biopsies. Credit: National Cancer Institute / Unsplash.

Biofidelity has raised $23m in a heavily oversubscribed Series A+ funding round for the upcoming launch of its first commercial diagnostic assay, ASPYRE-Lung.

Octopus Ventures led the round, which was backed by SBI Investment along with existing investors.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Developed based on the company’s molecular technology, the assay enables the detection of key genetic mutations from tissue or liquid biopsies.

This simplifies and accelerates the detection of genomic biomarkers.

Biofidelity developed the new technology to run on existing PCR machines, the instruments that are used for Covid-19 tests.

This makes the comprehensive analysis of genomic biomarkers accessible for patients worldwide.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The analysis provided by the assay will help physicians identify patients who may benefit from cancer therapies.

This will lead to better outcomes for patients, reduced side effects and improved survival rates.

Biofidelity CEO Dr Barnaby Balmforth said: “Our mission is to ensure that all patients diagnosed with cancer have access to the genomic information they need to receive the best possible treatment.

“This financing is an important step towards making this vision a reality, enabling us to launch our revolutionary technology and to make comprehensive biomarker testing faster, more affordable and more accessible than ever before.”

The company stated that while its initial focus is on non-small cell lung cancer (NSCLC), it also aims to expand the new technology to broad application across the cancer testing market.

In May 2020, Biofidelity raised $12m in a Series A financing round that was supported by Agilent Technologies, BlueYard Capital and Longwall Ventures.

The latest round brings Biofidelity’s total funding raised to $36m.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
HemoSonics has won the 2025 Marketing Award for its impactful promotion of theQuantra Hemostasis System and leadership in blood management education. See how targeted campaigns, thought leadership content, and hands on clinician training are accelerating Quantra’s market traction and shaping the future of hemostasis testing.

Discover the Impact